Cell Therapy and Protein Good Manufacturing Practice Facility
At the GBF we collaborate with basic science and clinical investigators to successfully translate laboratory discoveries into early phase clinical trials.
The Gates Biomanufacturing Facility at the University of Colorado Anschutz Medical Campus is a 14,000 square ft. GMP compliant manufacturing facility that provides cell-based therapies and protein biologics for use in preclinical investigations and Phase I and Phase II human clinical trials. The GBF was established in 2015 though partnership with the Gates Center for Regenerative Medicine, University of Colorado Health, Children’s Hospital Colorado, University of Colorado-School of Medicine, and the Gates Frontiers Fund.
- Cell-Based Therapies
- Protein Biologics
- Quality Assurance
- Quality Control
- Regulatory support
- Academic Researchers
- Early Stage Biotechnology Companies
- Established Pharmaceutical Companies
Recent Gates Biomanufacturing Facility News
This facility allows the production of both cell therapies and biologics and is the only one of this caliber in an 800-mile radius. There are 25 other academic facilities that follow Good Manufacturing Practices (GMP) in the United States, only 5 of which are comparable to the quality and functionality of GBF, making GBF both geographically and functionally unique.
The vision of the Gates family is being realized at the Gates Center, which took a giant step forward last month when it opened the Gates Biomanufacturing Facility (GBF). It not only will help provide cell-based therapies for patients with cancer, cardiovascular disease, HIV, influenza, skin diseases and others, but also furthers CU Anschutz as one of the world's leading academic medical facilities and a major health care destination.
The Gates Center for Regenerative Medicine is a 74-member consortium of individuals from CU Anschutz, National Jewish Health, CU Boulder, Colorado State University, Colorado School of Mines and businesses. The Gates Center has secured financing for the new $17-million biomanufacturing facility through 2018.